What validation data can be shown concerning the applications?
KINAXO Cellular Target Profiling® Technology has been validated in collaborations with leading pharmaceutical and biotechnology companies, e.g. JNJ, Bayer HealthCare, UCB and Onconova. Examples include clinical candidate optimization and selection, target identification, drug re-profiling and drug rescue. KINAXO Cellular Target Profiling® results have been presented at international conferences (e.g. AACR) and will be jointly published with our clients in peer-reviewed journals. For technical validation, we have performed KINAXO Cellular Target Profiling® in-house case studies on marketed drugs (e.g. Nexavar®, Sprycel®). These studies demonstrate that KINAXO Cellular Target Profiling® correlates very well with the observed biological effects and published data. KINAXO’s KinAffinity® Technology has been validated by in-house case studies on well-characterized multi-specific kinase inhibitors (e.g. SKI-606, Sprycel®), delivering results that are consistent with published data. Collaborat
